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DOI 10.1016/j.chembiol.2011.04.005Since the human genome was published
10 years ago, the hunt has been on in
industry and academia to find the genetic
basis for human disease. The genome
includes the DNA sequence, the strings
of nucleic acids coding our genetic inher-
itance. But over the years, researchers
started looking at another layer of heri-
table influence, the epigenome that acts
by controlling pathways involved turning
genes on and off. And a small company
based in Cambridge, MA, is hoping they’ll
be the one—or at least one of the compa-
nies—to find commercial success in
developing new drugs for cancer based
on new targets of the epigenome.
Epizyme got its start in mid 2008 and is
among the first biotechnology companies
with its sole focus on exploiting epigeneticEpizyme’s strategy is to focus on the ‘‘HMTome’’—the collection
of the body’s histone methytransferase (HMT) enzymes.discoveries to develop new medicines.
Broadly, epigenetics involves a series of
changes involving chemical modifications
to the cell’s chromatin, the DNA and
related proteins found in the nucleus of
each cell. Thesemodifications do not alter
the underlying DNA sequence. Instead,
they act on controlling gene transcription,
or the process of whether a gene is acti-
vated or suppressed. Epizyme’s goal is
to find ways that influence gene transcrip-
tion control.
In 2007, Epizyme’s founders, Nobel
Laureate Robert Horvitz of MIT and Yi
Zhang of the University of North Carolina,
advised Epizyme’s potential investors into
taking the new epigenetic biology forward
into a company focused on epigenetic
enzymes. In particular, Zhang’s academic
work was instrumental in identifying
specific chromatin-modifying enzymes
that appeared to be playing driving roles
in human diseases.
Today, Epizyme employs about 30
people in R&D, including five medicinal




In a 2009 review article, Epizyme re-
searchers summarized the universe of
enzymatic epigenetic modifiers to include
DNA methyltransferases (DNMTs), which
methylate the carbon atom at the 5-posi-
tion of cytosine in the CpG dinucleotide
sites of the genome; protein methyltrans-
ferases (PMTs), which methylate lysine or
arginine residues on histones and other
proteins; protein demethylases, which
remove methyl groups from the lysine or
arginine residues of proteins; histone ace-
tyltransferases, which acetylate lysine
residues on histones and other proteins;histone deacetylases (HDACs), which
remove acetyl groups from lysine resi-
dues on histones and other proteins;
ubiquitin ligases, which add ubiquitin to
lysine residues on histones and other
proteins; and specific kinases that phos-
phorylate serine residues on histones
(Copeland et al., 2009).
Other companies are already out in
front developing and marketing small-
molecule inhibitors against HDACs (vori-
nostat, romidepsin) and DNMTs (azacita-
dine, decitabine). Epizyme’s strategy is
to focus on the ‘‘HMTome’’—the collec-
tion of the body’s histone methytransfer-
ase (HMT) enzymes. ‘‘We believe that
the epigenetic enzymes, in particular the
HMTs, afford a valuable pharmacological
basis for intervening in aberrant gene
transcription,’’ explains Robert Copeland,
Ph.D., Epizyme’s chief scientific officer.
For those individuals in the future found
to have disease involving abnormal meth-
ylation, targeted HMT inhibition might
provide a highly effective route to correct-
ing abnormal gene function. ‘‘TargetingChemistry & Biology 18, April 22, 2011HMTs is a way to develop personally
targeted medicines that are defined
by specific genetic alterations,’’ adds
Copeland.
HMTs are a very large family of
enzymes with an estimated 96 individual
types found in the human genome.
Epizyme has chosen to begin its HMT
mining starting with HMTs that are genet-
ically altered in specific patient popula-
tions, like cancer.
Using publicly available genomic data-
bases, including the Cancer Genome
Atlas database, and the insight of
academic collaborators, Epizyme is look-
ing for genetic alterations in HMTs, such
as gene amplification, specific point
mutations, or mutations in associated
proteins or pathways. ‘‘We are looking
for situations in which a specific cancer
is being driven by a genetic alteration in
a specific HMT or in the pathway that is
impacted by an HMT,’’ says Copeland.
‘‘We are doing this so that we can identify
patients that we know are likely to benefit
from a specific therapy and then develop
a small molecules to address that need.’’
Of the 96 known human HMTs,
Epizyme’s lead drug discovery efforts
target DOT1L and EZH2. In a recent
report, Epizyme researchers described
an EZH2 point mutations among a subset
of NHL patients (Sneeringer et al., 2010).
They found that patients with disease
had a combination of mutant enzyme
and wild-type enzyme that led to disease.
‘‘The two in concert is what causes the
disease,’’ says Copeland. ‘‘We believe
this is the first example of a human
disease in which there is a required
coupling of a wild-type and mutant
enzyme. We have been able to translate
that finding into an EZH2 drug discovery
effort.’’ Similarly, in cancer, DOT1L
activity has been identified in a certain
type of leukemia called mixed lineage
leukemia.
But the company is not solely investi-
gating DOT1L and EZH2. Their platform
technology includes a universal mecha-
nism for assaying HMT targets. ‘‘Withª2011 Elsevier Ltd All rights reserved 403
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in place a cross-screening panel where
today we have 14 of the 96 human
HMTs in a panel with robust biochemical
pathways,’’ explains Copeland. ‘‘That
allows us to take every compound we
create and test it against every enzyme.’’
Using this technique, the company claims
to have discovered potent and selective
inhibitors for 12 of the 14 enzymes so far.
New Biology, New Challenges, Lots
of Anticipation
Epizyme will face the common hurdles
of translating inhibitors of a target into
therapeutically valuable entities, including
pharmacokinetic properties and all of the
things that make a compound usable as
a medicine in people. Before that, they
face the additional burden of proving
in vivo efficacy in animal models for an
unprecedented target. Though not yet
published, the company does claim to
have in vivo proof of concept data
backing up its approach.
‘‘Targeting the epigenome has already
been done successfully,’’ explains Jean-
Pierre Issa, Co-Director of the Center for
Cancer Epigenetics, Professor in the
Department of Leukemia, and Chief of
Translational Research at MD Anderson
Cancer Center, who has conducted clin-
ical trials of the HDACs and DNMTs. ‘‘I
would be excited about clinical trials of
the next generation of those drugs.’’
But he cautions against haste. ‘‘In
general, people have some concerns
regarding the specificity of epigenetic
targeting. The next-generation drugs are
looking at a narrow target, like a particular
HMT. Even this may be nonspecific since404 Chemistry & Biology 18, April 22, 2011 ªHMTs may have a lot of downstream
effects we are not always aware of,’’ he
says. ‘‘It is theoretically possible that it’s
not a good idea to reactivate those genes.
This has been the issue that has plagued
epigenetics for a while.’’
Issa adds that recent history with epige-
netic agents has been mixed. ‘‘Those in
the field have been very worried because
much of the drugs that have been
available so far really target the whole
genome and don’t do anything specifi-
cally for cancer,’’ he says. ‘‘Although this
approach really has worked and many
drugs are FDA approved, there are
concerns that the nonspecificity may
perhaps in some cases promote tumors
and limit how long we can give these
drugs in cancer prevention, and so on.’’
He hopes this concern will be allayed by
the next generation of drugs.
Perhaps the real promise in epigenetics
has been afforded by discoveries fueled
by next-generation DNA sequencing,
whichhasgreatly increased theavailability
of genomic information. ‘‘We have known
for a while that mutant genes, particularly
active mutating genes, are great targets
for drug development—they indicate
Achilles heels of tumors and provide
markers for who to treat and so on,’’
adds Issa. ‘‘With our understanding from
next-gen sequencing, it turns out there
are more mutations in epigenetic regula-
tors than any other class of proteins in
cancer. This has really heightened interest
in these targeted drugs.’’
Partners with Big Pharma
Big pharma has certainly noticed the
promise of epigenetics and Epizyme,2011 Elsevier Ltd All rights reservedin particular. In January 2011, Glaxo-
SmithKline (GSK) formed a partnership
with Epizyme worth potentially up to
$630 million. The deal charges Epizyme
with identifying an unstated number of
specific targets, excluding DOT1L and
EZH2, and identifying small-molecule
HMT inhibitors that are pharmacologically
tractable for clinical use. ‘‘This is obvi-
ously a significant opportunity for Epi-
zyme,’’ says Copeland, who is a former
vice president in the cancer biology
program at GSK.
In March 2011, Epizyme made an alli-
ance with Japanese health care products
company Eisai Co., Ltd, focusing solely
on theEZH2 target for cancer therapeutics.
Eisai will provide up to $200 million to
Epizyme based on progress in developing
new treatments for lymphoma and other
cancers in genetically defined patients.
Epizyme’s small molecule collection
numbers > 6,000—its first steps toward
its vision of translating epigenetic science
into the next generation of personalized
medicine.
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